cheaptrix/billsum-US_congress_and_house huggingface dataset:
RARE Act

To amend the Federal Food, Drug, and Cosmetic Act to set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions. 1. Short title This Act may be cited as the Retaining Access and Restoring Exclusivity Act RARE Act 2. Limitations on exclusive approval or licensure of orphan drugs (a) In general Section 527 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360cc (1) in subsection (a), in the matter following paragraph (2), by striking same disease or condition same approved use or indication within such rare disease or condition (2) in subsection (b)— (A) in the matter preceding paragraph (1), by striking same rare disease or condition same approved use or indication for which such 7-year period applies to such already approved or licensed drug (B) in paragraph (1), by inserting , relating to the approved use or indication, the needs (3) in subsection (c)(1), by striking same rare disease or condition as the already approved drug same use or indication for which the already approved or licensed drug was approved or licensed (4) by adding at the end the following: (f) Approved use or indication defined In this section, the term approved use or indication . (b) Application of amendments The amendments made by subsection (a) shall apply with respect to any drug designated under section 526 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bb 21 U.S.C. 355 42 U.S.C. 262

Summary: Retaining Access and Restoring Exclusivity Act or the RARE Act This bill specifies that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drug exclusivity period) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. Current law grants a seven-year period of market exclusivity for an approved orphan drug, during which the Food and Drug Administration (FDA) may not approve an application from another manufacturer for the same drug for the same disease or condition. The FDA's regulations provide that this exclusivity is specific to the same approved use or indication of the drug, rather than all uses or indications, for the disease or condition. However, in Catalyst Pharmaceuticals, Inc. v. Becerra, a court held that exclusivity did extend to all uses or indications for the disease or condition. The bill provides statutory authority for the FDA's regulations.
Creating Hope Reauthorization Act of 2024

To amend the Federal Food, Drug, and Cosmetic Act to extend the authority of the Secretary of Health and Human Services to issue priority review vouchers to encourage treatments for rare pediatric diseases. 1. Short title This Act may be cited as the Creating Hope Reauthorization Act of 2024 2. Extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases Section 529(b)(5) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360ff(b)(5) (1) by striking September 30, 2024 September 30, 2028 (2) in subparagraph (B), by striking September 30, 2026 September 30, 2030

Summary: Creating Hope Reauthorization Act of 2024 This bill extends until FY2029 a Food and Drug Administration program that awards priority review vouchers to manufacturers of drugs that treat rare pediatric diseases. (A priority review voucher entitles the voucher holder to priority review of a single human drug application.)
For the relief of Tetyana Zvarychuk.

For the relief of Tetyana Zvarychuk. 1. Permanent resident status for Tetyana Zvarychuk (a) In general Notwithstanding subsections (a) and (b) of section 201 of the Immigration and Nationality Act, Tetyana Zvarychuk shall be eligible for issuance of an immigrant visa or for adjustment of status to that of an alien lawfully admitted for permanent residence upon filing an application for issuance of an immigrant visa under section 204 of such Act or for adjustment of status to lawful permanent resident. (b) Adjustment of status If Tetyana Zvarychuk enters the United States before the filing deadline specified in subsection (c), she shall be considered to have entered and remained lawfully and shall, if otherwise eligible, be eligible for adjustment of status under section 245 of the Immigration and Nationality Act as of the date of the enactment of this Act. (c) Deadline for application and payment of fees Subsections (a) and (b) shall apply only if the application for issuance of an immigrant visa or the application for adjustment of status is filed with appropriate fees within 2 years after the date of the enactment of this Act. (d) Reduction of immigrant visa number Upon the granting of an immigrant visa or permanent residence to Tetyana Zvarychuk, the Secretary of State shall instruct the proper officer to reduce by 2, during the current or next following fiscal year, the total number of immigrant visas that are made available to natives of the country of the alien’s birth under section 203(a) of the Immigration and Nationality Act or, if applicable, the total number of immigrant visas that are made available to natives of the country of the alien’s birth under section 202(e) of such Act. (e) Denial of preferential immigration treatment for certain relatives The natural parents, brothers, and sisters of Tetyana Zvarychuk shall not, by virtue of such relationship, be accorded any right, privilege, or status under the Immigration and Nationality Act.

Summary: Provides for the relief of Tetyana Zvarychuk.
To amend title XVIII of the Social Security Act to establish a definition of essential health system in statute.

To amend title XVIII of the Social Security Act to establish a definition of essential health system in statute. 1. Establishing a definition of essential health system in statute Section 1861 of the Social Security Act ( 42 U.S.C. 1395x (nnn) Essential health system The term essential health system (1) that is a subsection (d) hospital (as defined in section 1886(d)(1)(B)); (2) that is a non-Federal governmental or private nonprofit hospital; and (3) that— (A) meets the requirements of a Medicaid deemed disproportionate share hospital (as described in section 1923(b)(1)); (B) has a Medicare disproportionate patient percentage of at least 35 percent (as defined in section 1886(d)(5)(F)(vi)); or (C) has a Medicare disproportionate share hospital uncompensated care payment factor of 0.0005 or more, (as defined in section 1886(r)(2)(C)). .

Summary: This bill establishes a statutory definition for essential health system under Medicare.Under the bill, an essential health system is one that (1) is an acute care hospital that is paid under Medicare's inpatient prospective payment system (excluding children’s, inpatient psychiatric, long-term care, rehabilitation hospitals, and certain cancer hospitals); (2) is a non-federal governmental or private nonprofit hospital; and (3) is a Medicaid disproportionate share hospital, has a Medicare disproportionate patient percentage of at least 35%, or has a Medicare disproportionate share hospital uncompensated care payment factor of 0.0005 or more.
ACSE Act

To terminate the American Community Survey, and for other purposes. 1. Short title This Act may be cited as the American Community Survey Elimination Act ACSE Act 2. Termination of American Community Survey The Secretary of Commerce or the Bureau of the Census may not carry out the American Community Survey, and no Federal funds may be obligated or expended to carry out such Survey (or any similar survey).

Summary: American Community Survey Elimination Act or the ACSE ActThis bill prohibits the Department of Commerce or the U.S. Census Bureau from carrying out the American Community Survey (ACS) and bars the obligation or expenditure of federal funds to carry out that survey or any similar survey. Currently, the ACS is conducted on a rolling basis by the Census Bureau and covers topics not included on the decennial census, such as education, military service, and internet access.
For the relief of Igor Klyuchenko.

For the relief of Igor Klyuchenko. 1. Permanent resident status for Igor Klyuchenko (a) In general Notwithstanding subsections (a) and (b) of section 201 of the Immigration and Nationality Act, Igor Klyuchenko shall be eligible for issuance of an immigrant visa or for adjustment of status to that of an alien lawfully admitted for permanent residence upon filing an application for issuance of an immigrant visa under section 204 of such Act or for adjustment of status to lawful permanent resident. (b) Adjustment of status If Igor Klyuchenko enters the United States before the filing deadline specified in subsection (c), he shall be considered to have entered and remained lawfully and shall, if otherwise eligible, be eligible for adjustment of status under section 245 of the Immigration and Nationality Act as of the date of the enactment of this Act. (c) Deadline for application and payment of fees Subsections (a) and (b) shall apply only if the application for issuance of an immigrant visa or the application for adjustment of status is filed with appropriate fees within 2 years after the date of the enactment of this Act. (d) Reduction of immigrant visa number Upon the granting of an immigrant visa or permanent residence to Igor Klyuchenko, the Secretary of State shall instruct the proper officer to reduce by 2, during the current or next following fiscal year, the total number of immigrant visas that are made available to natives of the country of the alien’s birth under section 203(a) of the Immigration and Nationality Act or, if applicable, the total number of immigrant visas that are made available to natives of the country of the alien’s birth under section 202(e) of such Act. (e) Denial of preferential immigration treatment for certain relatives The natural parents, brothers, and sisters of Igor Klyuchenko shall not, by virtue of such relationship, be accorded any right, privilege, or status under the Immigration and Nationality Act.

Summary: Provides for the relief of Igor Klyuchenko.
Inflation Relief Act

To amend the Internal Revenue Code of 1986 to provide individuals a refundable credit for a portion of Federal income tax liability for 2024. 1. Short title This Act may be cited as the Inflation Relief Act 2. Refundable credit for portion of individual Federal income tax liability for 2024 (a) In general Subpart C of part IV of subchapter A of chapter 1 36C. Credit for portion of individual Federal income tax liability for 2024 (a) In general In the case of an individual, there shall be allowed as a credit against the tax imposed by this subtitle for any taxable beginning after December 31, 2023, and before January 1, 2025, an amount equal to 10 percent of the taxpayer’s Federal income tax liability for such taxable year. (b) Limitation based on modified adjusted gross income Subsection (a) shall not apply to any taxpayer for any taxable year if the taxpayer’s modified adjusted gross income (as defined in section 36(b)(2)(B)) exceeds— (1) in the case of a joint return, $250,000, (2) in the case of a married individual filing a separate return, $125,000, and (3) in any other case, $150,000. (c) Federal income tax liability For purposes of this section, the term Federal income tax liability (1) the sum of the amounts described in paragraphs (1) and (2) of section 26(a), over (2) the sum of the credits allowed under subpart A of this part. . (b) Conforming amendments (1) Section 6211(b)(4)(A) 36C, 36B, (2) Paragraph (2) of section 1324(b) of title 31, United States Code, is amended by inserting 36C, 36B, (3) The table of sections for subpart C of part IV of subchapter A of chapter 1 Sec. 36C. Credit for portion of individual Federal income tax liability for 2024. . (c) Effective date The amendments made by this section shall apply to taxable years beginning after December 31, 2023.

Summary: Inflation Relief Act This bill allows a refundable income tax credit for 10% of federal tax liability for a taxable year beginning in 2024. The credit is not available to taxpayers whose modified adjusted gross income exceeds $150,000 ($250,000 for joint tax returns) in any taxable year.
To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants.

To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. 1. Exclusion of compensation provided to participants in clinical trials (a) In general Part III of subchapter B of chapter 1 139J. Clinical trial payments (a) In general Gross income shall not include any amount received by an individual as a qualified clinical trial payment. (b) Qualified clinical trial payment defined For purposes of this section, the term qualified clinical trial payment (1) as compensation for participation by the individual or a dependent of the individual in an approved clinical trial, or (2) to reimburse or pay reasonable and necessary expenses incurred in connection with participation by the individual or a dependent of the individual in an approved clinical trial. (c) Other definitions For purposes of this section— (1) Approved clinical trial The term approved clinical trial 42 U.S.C. 300gg–8(d)(1) disease or condition life-threatening disease or condition (2) Dependent The term dependent . (b) Clerical amendment The table of sections for part III of subchapter B of chapter 1 of such Code is amended by inserting after the item relating to section 139I the following new item: Sec. 139J. Clinical trial payments. . (c) Effective date The amendment made by this section shall apply to amounts paid after December 31, 2023.

Summary: This bill excludes from gross income, for income tax purposes, any amount received by an individual as a qualified clinical trial payment. Such payments include amounts paid to an individual or a dependent of the individual as compensation for participation in an approved clinical trial (i.e., a trial conducted in relation to the prevention, detection, or treatment of cancer or other disease or condition) or as reimbursement or payment of reasonable and necessary expenses incurred in connection with the individual's participation in an approved clinical trial.
FORCE Act

To require the Secretary of Defense to submit a report on the quality of overseas covered military unaccompanied housing, and for other purposes. 1. Short title This Act may be cited as the Foreign Overseas Residence Conditions Enhancement Act FORCE Act 2. Findings Congress finds the following: (1) According to a September 2023 Government Accountability Office report (23–107038) that surveyed 31 military installations within the United States, the Department of Defense does not reliably assess the conditions of barracks on installations, many of which are substandard and pose potentially serious health and safety risks to residents. (2) The Department of Defense also does not have complete visibility into the funding needed for construction and maintenance of unaccompanied housing facilities. (3) The Department of Defense does not conduct sufficient oversight needed to address long-standing challenges with conditions in barracks. (4) The purview of this report related to barracks on installations within the United States, but did not survey any overseas barracks facilities operated by the Department of Defense. (5) It is the opinion of Congress that American servicemembers deserve the highest possible quality of residential facilities that do not endanger mission readiness or capability. 3. Report on overseas covered military unaccompanied housing (a) Report requirements Not later than 180 days after the date of the enactment of this Act, the Secretary of Defense shall submit to the Committees on Armed Services of the Senate and House of Representatives a report on the quality of all covered military unaccompanied housing not located in the United States that shall include the following: (1) The results of an evaluation the condition of such housing using the uniform index developed under section 2838 of the National Defense Authorization Act for Fiscal Year 2024 ( Public Law 118–31 (2) A explanation of how the standards for habitability established under section 2856b of title 10, United States Code (as added by section 2832 of the National Defense Authorization Act for Fiscal Year 2024 ( Public Law 118–31 (3) An assessment to determine the funding needed to apply the standards for habitability described in paragraph (2) to such housing. (4) An assessment of how habitability standards and the condition of such housing affect force readiness, broken down by combatant command. (b) Covered military unaccompanied housing defined In this subsection, the term covered military unaccompanied housing

Summary: Foreign Overseas Residence Conditions Enhancement Act or the FORCE Act This bill requires the Department of Defense to report on the quality of all military unaccompanied housing not located in the United States (i.e., government-owned military housing that is intended to be occupied by members of the Armed Forces serving a tour of duty unaccompanied by dependents).
TELL Act

To require that any person that maintains an internet website or that sells or distributes a mobile application that stores and maintains information collected from such website or application in the People’s Republic of China to disclose that such information is stored and maintained in the People’s Republic of China and whether the Chinese Communist Party or a Chinese State-owned entity has access to such information. 1. Short title This Act may be cited as the Telling Everyone the Location of data Leaving the U.S. Act TELL Act 2. Country disclosure requirements (a) Disclosure requirements Any person that maintains an internet website or that sells or distributes a mobile application that stores and maintains information collected from such website or application in the People’s Republic of China shall disclose to any individual who downloads or otherwise uses such website or application, in a clear and conspicuous manner, the following: (1) That such information is stored and maintained in the People’s Republic of China. (2) Whether the Chinese Communist Party or a Chinese State-owned entity has access to such information. (b) False information It shall be unlawful for a person required to disclose information under subsection (a) to knowingly disclose false information under such subsection. 3. Enforcement (a) Unfair or deceptive acts or practices A violation of this Act shall be treated as a violation of a rule defining an unfair or deceptive act or practice prescribed under section 18(a)(1)(B) of the Federal Trade Commission Act ( 15 U.S.C. 57a(a)(1)(B) (b) Powers of Federal Trade Commission (1) In general The Federal Trade Commission shall enforce this Act in the same manner, by the same means, and with the same jurisdiction, powers, and duties as though all applicable terms and provisions of the Federal Trade Commission Act ( 15 U.S.C. 41 et seq. (2) Privileges and immunities Any person that violates this Act shall be subject to the penalties, and entitled to the privileges and immunities, provided in the Federal Trade Commission Act ( 15 U.S.C. 41 et seq.

Summary: Telling Everyone the Location of data Leaving the U.S. Act or the TELL Act This bill requires any person that maintains a website or that sells or distributes a mobile application that maintains and stores information in China to conspicuously disclose certain information to individuals who download or otherwise use the website or application. The disclosures must specify (1) that such information is stored and maintained in China, and (2) whether the information is accessible by the Chinese Communist Party or a Chinese state-owned entity. The bill also provides for enforcement of these requirements by the Federal Trade Commission.
BEST for Vets Act of 2024

To ensure that only licensed health care professionals furnish disability examinations under a certain Department of Veterans Affairs pilot program for use of contract physicians for disability examinations, and for other purposes. 1. Short title This Act may be cited as the Better Examiner Standards and Transparency for Veterans Act of 2024 BEST for Vets Act of 2024 2. Ensuring only licensed health care professionals furnish medical disability examinations under certain Department of Veterans Affairs pilot program for use contract physicians for disability examinations (a) Prohibition on use of certain health care professionals Section 504(a) of the Veterans' Benefits Improvements Act of 1996 ( Public Law 104–275 38 U.S.C. 5101 (1) by striking The Secretary of Veterans Affairs (1) In general The Secretary of Veterans Affairs ; and (2) by adding at the end the following new paragraph: (2) Prohibition No examination described in paragraph (1) may be carried out under this section by any health care professional other than one described in subsection (c)(2). . (b) Remedies The Secretary of Veterans Affairs shall take such actions as the Secretary considers appropriate to ensure that only health care professionals described in subsection (c)(2) of section 504 of the Veterans' Benefits Improvements Act of 1996 ( Public Law 104–275 38 U.S.C. 5101 (c) Annual report Not later than one year after the date of the enactment of this Act and not less frequently than once each year thereafter, the Secretary shall submit to the Committee on Veterans' Affairs of the Senate and the Committee on Veterans' Affairs of the House of Representatives a report on— (1) the conduct of the pilot program established under section 504 of the Veterans' Benefits Improvements Act of 1996 ( Public Law 104–275 38 U.S.C. 5101 (2) the actions of the Secretary under subsection (b). (d) Technical corrections Section 504 of the Veterans' Benefits Improvements Act of 1996 ( Public Law 104–275 38 U.S.C. 5101 physicians health care professionals

Summary: Better Examiner Standards and Transparency for Veterans Act of 2024 or the BEST for Vets Act of 2024 This bill provides that only health care professionals who are licensed and not barred from practice may furnish medical disability examinations under the Department of Veterans Affairs pilot program related to using contract physicians for disability examinations. Health care professionals include physicians, physician assistants, nurse practitioners, audiologists, and psychologists.
Philippine Medicare Portability Study Act

To direct the Comptroller General of the United States to conduct a study to assess the feasibility and financial effects of expanding coverage under the Medicare program to items and services furnished in the Philippines. 1. Short title This Act may be cited as the Philippine Medicare Portability Study Act 2. GAO study and report Not later than the date that is 180 days after the date of the enactment of this Act, the Comptroller General of the United States shall submit to Congress a report on the feasibility and financial effects of expanding coverage under the Medicare program under title XVIII of the Social Security Act ( 42 U.S.C. 1395 et seq. (1) The estimated cost savings to the Medicare program that would be realized during the period beginning January 1, 2025, and ending December 31, 2034, through payment for such items and services pursuant to such expansion of coverage, as compared to the likely costs of payment for such items and services within the United States during such period. (2) A description of the legislative and administrative changes to the Medicare program that would be required in order for such expansion of coverage to be implemented.

Summary: Philippine Medicare Portability Study ActThis bill requires the Government Accountability Office to report on the feasibility and financial effects of expanding Medicare coverage to include items and services that are provided in the Philippines.The report must include the estimated cost savings to Medicare from 2025 through 2034, as well as a description of any necessary legislative and administrative changes that would be required to expand coverage.